Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group

Article metrics

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2

References

  1. 1

    Döhner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.

  2. 2

    Higuchi M, O’Brien D, Kumaravelu P, Lenny N, Yeoh E-J, Downing JR . Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1: 63–74.

  3. 3

    Schlenk RF, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22: 3741–3750.

  4. 4

    Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 5705–5717.

  5. 5

    Krauth M-T, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia 2014; 28: 1449–1458.

  6. 6

    Huether R, Dong L, Chen X, Wu G, Parker M, Wei L et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun 2014; 5: 3630.

  7. 7

    Katoh M . Functional and cancer genomics of ASXL family members. Br J Cancer 2013; 109: 299–306.

  8. 8

    Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci M-J, Birnbaum D . Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012; 5: 12.

  9. 9

    Abdel-Wahab O, Levine RL . Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013; 121: 3563–3572.

  10. 10

    Micol J-B, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O et al. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood 2014; 124: 1445–1450.

  11. 11

    Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J . The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet 2016; 48: 1551–1556, in press.

  12. 12

    Chou W-C, Huang H-H, Hou H-A, Chen C-Y, Tang J-L, Yao M et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 2010; 116: 4086–4094.

  13. 13

    Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L et al. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica 2015; 100: 324–330.

  14. 14

    Pratcorona M, Abbas S, Sanders MA, Koenders JE, Kavelaars FG, Erpelinck-Verschueren CA et al. Acquired mutations in ASXL1 in acute myeloid leukemia: Prevalence and prognostic value. Haematologica 2012; 97: 388–392.

  15. 15

    Micol J-B, Duployez N, Pastore A, Williams R, Kim E, Lee S et al. ASXL2 is a novel mediator of RUNX1-ETO transcriptional function and collaborates with RUNX1-ETO to promote leukemogenesis. Blood 2015; 126: 302.

Download references

Acknowledgements

This work was supported in part by grants from the Deutsche Krebshilfe (No. 109675).

Author contributions

Conception and design: Nikolaus Jahn, Peter Paschka and Konstanze Döhner. Provision of study materials or patients: Nikolaus Jahn, Mridul Agrawal, Lars Bullinger, Daniela Weber, Andrea Corbacioglu, Verena I Gaidzik, Laura Schmalbrock, Felicitas Thol, Michael Heuser, Jürgen Krauter, Gudrun Göhring, Andrea Kündgen, Walter Fiedler, Mohammed Wattad, Gerhard Held, Claus-Henning Köhne, Heinz-A Horst, Michael Lübbert, Arnold Ganser, Richard F Schlenk, Hartmut Döhner, Konstanze Döhner and Peter Paschka. Collection and assembly of data: Richard F Schlenk, Daniela Weber, Nikolaus Jahn, Peter Paschka and Konstanze Döhner. Data analysis and interpretation: Daniela Weber, Nikolaus Jahn, Hartmut Döhner, Peter Paschka and Konstanze Döhner. Manuscript writing: Nikolaus Jahn, Peter Paschka and Konstanze Döhner. Final approval of manuscript: Nikolaus Jahn, Mridul Agrawal, Lars Bullinger, Daniela Weber, Andrea Corbacioglu, Verena I Gaidzik, Laura Schmalbrock, Felicitas Thol, Michael Heuser, Jürgen Krauter, Gudrun Göhring, Andrea Kündgen, Walter Fiedler, Mohammed Wattad, Gerhard Held, Claus-Henning Köhne, Heinz-A Horst, Michael Lübbert, Arnold Ganser, Richard F Schlenk, Hartmut Döhner, Konstanze Döhner and Peter Paschka.

Author information

Correspondence to P Paschka.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading